Switch theme
Sign up to access all valuation multiples
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
2021
2.1K+
LTM Revenue $1.1B
LTM EBITDA $375M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Embecta has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $375M.
In the most recent fiscal year, Embecta achieved revenue of $1.1B and an EBITDA of $193M.
Embecta expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Embecta valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | XXX | XXX | XXX |
| Gross Profit | $775M | $750M | XXX | XXX | XXX |
| Gross Margin | 69% | 67% | XXX | XXX | XXX |
| EBITDA | $245M | $193M | XXX | XXX | XXX |
| EBITDA Margin | 22% | 17% | XXX | XXX | XXX |
| Net Profit | $224M | $70.4M | XXX | XXX | XXX |
| Net Margin | 20% | 6% | XXX | XXX | XXX |
| Net Debt | $1.3B | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Embecta's stock price is $12.
Embecta has current market cap of $692M, and EV of $2.1B.
See Embecta trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $692M | XXX | XXX | XXX | XXX | $2.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Embecta has market cap of $692M and EV of $2.1B.
Embecta's trades at 1.9x LTM EV/Revenue multiple, and 5.5x LTM EBITDA.
Analysts estimate Embecta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Embecta and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.5x | XXX | XXX | XXX |
| P/E | 7.9x | XXX | XXX | XXX |
| P/E/Growth | 0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEmbecta's NTM/LTM revenue growth is -1%
Embecta's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Embecta's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Embecta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Embecta and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 40% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Embecta acquired XXX companies to date.
Last acquisition by Embecta was XXXXXXXX, XXXXX XXXXX XXXXXX . Embecta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Embecta founded? | Embecta was founded in 2021. |
| Where is Embecta headquartered? | Embecta is headquartered in United States of America. |
| How many employees does Embecta have? | As of today, Embecta has 2.1K+ employees. |
| Who is the CEO of Embecta? | Embecta's CEO is Mr. Devdatt Kurdikar, PhD. |
| Is Embecta publicy listed? | Yes, Embecta is a public company listed on NAS. |
| What is the stock symbol of Embecta? | Embecta trades under EMBC ticker. |
| When did Embecta go public? | Embecta went public in 2022. |
| Who are competitors of Embecta? | Similar companies to Embecta include e.g. Ansell, Polymed, Schott Pharma, Fresenius Medical Care. |
| What is the current market cap of Embecta? | Embecta's current market cap is $692M |
| What is the current revenue of Embecta? | Embecta's last 12-month revenue is $1.1B. |
| What is the current EBITDA of Embecta? | Embecta's last 12-month EBITDA is $375M. |
| What is the current EV/Revenue multiple of Embecta? | Current revenue multiple of Embecta is 1.9x. |
| What is the current EV/EBITDA multiple of Embecta? | Current EBITDA multiple of Embecta is 5.5x. |
| What is the current revenue growth of Embecta? | Embecta revenue growth between 2023 and 2024 was 0%. |
| Is Embecta profitable? | Yes, Embecta is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
